Sonoma Pharmaceuticals, Inc. (SNOA)
SNOA Stock Price Chart
Explore Sonoma Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze SNOA price movements and trends.
SNOA Company Profile
Discover essential business fundamentals and corporate details for Sonoma Pharmaceuticals, Inc. (SNOA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
25 Jan 2007
Employees
10.00
Website
https://www.sonomapharma.comCEO
Amy M. Trombly
Description
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.
SNOA Financial Timeline
Browse a chronological timeline of Sonoma Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 3 Feb 2026
Upcoming earnings on 6 Nov 2025
Earnings released on 7 Aug 2025
EPS came in at -$0.37 surpassing the estimated -$0.51 by +27.45%, while revenue for the quarter reached $4.02M , missing expectations by -5.75%.
Earnings released on 17 Jun 2025
EPS came in at -$0.15 surpassing the estimated -$0.73 by +79.45%, while revenue for the quarter reached $3.75M , missing expectations by -15.44%.
Earnings released on 5 Feb 2025
EPS came in at -$0.59 surpassing the estimated -$0.80 by +26.25%, while revenue for the quarter reached $3.56M , missing expectations by -19.73%.
Earnings released on 7 Nov 2024
EPS came in at -$0.59 surpassing the estimated -$1.00 by +41.00%, while revenue for the quarter reached $3.58M , missing expectations by -18.47%.
Stock split effective on 30 Aug 2024
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 8 Aug 2024
EPS came in at -$1.40 falling short of the estimated -$0.06 by -2.23K%, while revenue for the quarter reached $3.39M , missing expectations by -10.34%.
Earnings released on 17 Jun 2024
EPS came in at -$1.40 surpassing the estimated -$3.41 by +58.92%, while revenue for the quarter reached $3.44M , missing expectations by -13.59%.
Earnings released on 8 Feb 2024
EPS came in at -$1.20 falling short of the estimated -$0.21 by -471.43%, while revenue for the quarter reached $3.14M , missing expectations by -21.16%.
Earnings released on 13 Nov 2023
EPS came in at -$4.00 falling short of the estimated -$0.24 by -1.57K%, while revenue for the quarter reached $2.73M , missing expectations by -21.52%.
Earnings released on 10 Aug 2023
EPS came in at -$5.80 falling short of the estimated -$2.40 by -141.67%, while revenue for the quarter reached $3.43M , beating expectations by +1.41%.
Earnings released on 21 Jun 2023
EPS came in at -$4.60 , while revenue for the quarter reached $3.01M , missing expectations by -8.62%.
Earnings released on 14 Feb 2023
EPS came in at -$10.00 , while revenue for the quarter reached $2.94M .
Earnings released on 14 Nov 2022
EPS came in at -$3.80 , while revenue for the quarter reached $3.33M .
Earnings released on 11 Aug 2022
EPS came in at -$5.80 , while revenue for the quarter reached $3.98M .
Earnings released on 13 Jul 2022
EPS came in at -$19.00 , while revenue for the quarter reached $2.30M .
Earnings released on 11 Feb 2022
EPS came in at -$6.20 , while revenue for the quarter reached $2.90M .
Earnings released on 15 Nov 2021
EPS came in at -$0.80 , while revenue for the quarter reached $3.74M .
Earnings released on 16 Aug 2021
EPS came in at -$10.40 , while revenue for the quarter reached $3.68M .
Earnings released on 14 Jul 2021
EPS came in at -$32.80 , while revenue for the quarter reached $2.16M .
Earnings released on 16 Feb 2021
EPS came in at -$6.20 , while revenue for the quarter reached $4.94M .
Earnings released on 20 Nov 2020
EPS came in at $1.40 , while revenue for the quarter reached $5.77M .
SNOA Stock Performance
Access detailed SNOA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.